ALPS Advisors’s Astria Therapeutics ATXS Stock Holding History

ALPS Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-46,874	Closed	-$614K	–	1046
2025 Q4	$614K	Buy	46,874 +20,713	+79%	+$247K	﹤0.01%	675
2025 Q3	$190K	Sell	26,161 -4,263	-14%	-$28.8K	﹤0.01%	1008
2025 Q2	$163K	Sell	30,424 -13,020	-30%	-$63.1K	﹤0.01%	1014
2025 Q1	$232K	Sell	43,444 -2,186	-5%	-$15.3K	﹤0.01%	955
2024 Q4	$408K	Buy	+45,630	New	+$485K	﹤0.01%	681

ALPS Advisors's ATXS Position: Q1 2026 in Review

ALPS Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 46,874 shares — an estimated $614K sold.

ALPS Advisors first reported a position in ATXS in Q4 2024 and held it in 5 quarters. The position peaked at $614K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

ALPS Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
ALPS Advisors sold 46,874 Astria Therapeutics shares in Q1 2026, an estimated $614K.
ALPS Advisors first reported a position in Astria Therapeutics in Q4 2024 and held it in 5 quarters.
ALPS Advisors's Astria Therapeutics position peaked at $614K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.